Small particle steroid study

Submission date 21/12/2012	Recruitment status No longer recruiting	Prospecti Protocol
Registration date	Overall study status	Statistica
07/01/2013	Completed	[X] Results [] Individua
28/07/2015	Respiratory	

ively registered

- al analysis plan
- l participant data

Plain English summary of protocol

Background and study aims

The small airways (that carry air in and out of the lungs) have become increasingly important in asthma. We now have non-invasive tests of small airways function at our disposition, as well as inhaled drugs (containing smaller aerosol particles) targeting asthma at the level of the small airways. The aim of this study was to assess whether inhaled medications targeting the small airways offer any benefit over regular asthma drugs in terms of lung function (and more specifically small airways function) and asthma control. In addition the study will provide useful information about the inflammatory and structural alterations in the small airways.

Who can participate?

Non-smoking asthma patients, both male and female, over 18 years old on inhaled corticosteroids ("controller" drugs for asthma) and with abnormalities in the small airways can participate. Pregnant women were excluded from the study.

What does the study involve?

The study involved two patient groups: during a 15 week period the first group was treated with inhaled asthma medications targeting the small airways, whereas patients in the second group remained on regular asthma drugs. Lung function tests were performed before starting and after 3, 9 and 15 weeks. At each of those time point patients were also asked to fill out a short guestionnaire (5 minutes) about their asthma. Each of the four study visits took approximately 1 hour. The asthma treatment was not interrupted throughout the entire study.

What are the possible benefits and risks of participating?

Study medication will be provided without any cost. No additional side effects are expected from the study medication, other than those related to the regular asthma treatment patients are already on. There are no risks associated with the lung function testing.

Where is the study run from?

The study took place in the UZ Brussel's (university hospital) outpatient clinic.

When is the study starting and how long is it expected to run for? The study started in September 2009 and ran until August 2012.

Who is funding the study? This study was funded by UCB Pharma.

Who is the main contact? Dr Shane Hanon shane.hanon@uzbrussel.be

Contact information

Type(s) Scientific

Contact name Dr Shane Hanon

Contact details Laarbeeklaan 101 Brussels Belgium 1090 shane.hanon@uzbrussel.be

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title Small particle steroid study: a randomized double blind double dummy study

Study objectives

The residual lung function abnormalities in the small airways of the conductive and acinar lung zone could be smaller with the ultrafine anti-inflammatory aerosol [beclomethasone dipropionate (HFA-BDP); QVAR)] than with a regular anti-inflammatory aerosol [budesonide (DPI-BUD); Pulmicort TH)] in asthma patients with pre-existing small airways dysfunction.

Ethics approval required Old ethics approval format

Ethics approval(s) Medical Ethics Committee of UZ Brussel, 02/04/2009, ref: 2009/043, B.U.N. B14320096121 **Study design** Randomized double-blind double-dummy study

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet [available in Dutch and French]

Health condition(s) or problem(s) studied

Asthma / Small airways

Interventions

After a 3-week run-in on DPI-BUD patients are randomized to either arm 1 (DPI- BUD switched to BDP-HFA from wk 4 to wk 15) or to arm 2 (remaining on DPI-BUD)

The intervention takes 15 weeks.

Intervention Type

Drug

Phase Not Applicable

Drug/device/biological/vaccine name(s)

Qvar (beclomethasone dipropionate), Pulmicort (Budesonide)

Primary outcome measure

Change in Sacin (Multiple Breath Nitrogen Washout test). Sacin is a measure of ventilation heterogeneity in the acinar lung zone. Sacin increases with increasing heterogeneity. Measured at baseline and after 3, 9 and 15 weeks.

Secondary outcome measures

Alveolar and bronchial exhaled NO
Lung function parameters
Asthma control test (ACT) score
Measured at baseline and after 3, 9 and 15 weeks.

Overall study start date

01/09/2009

Completion date

31/08/2012

Eligibility

Key inclusion criteria

- 1. Well-established, stable asthma patients on inhaled corticosteroids
- 2. Age >18 years, male/female
- 3. Elevated baseline Sacin (>0.12 L-1)

Participant type(s) Patient

Age group Adult

Lower age limit 18 Years

Sex Both

Target number of participants 35

Key exclusion criteria 1. Smoking history (> 10 packyears) or current smokers 2. Pregnant women

Date of first enrolment

01/09/2009

Date of final enrolment 31/08/2012

Locations

Countries of recruitment Belgium

Study participating centre Laarbeeklaan 101 Brussels Belgium 1090

Sponsor information

Organisation University Hospital Brussels (Universitair Ziekenhuis Brussel [UZ Brussel]) (Belgium)

Sponsor details Laarbeeklaan 101 Brussels Belgium 1090

Sponsor type Hospital/treatment centre

Website http://www.uzbrussel.be

ROR https://ror.org/038f7y939

Funder(s)

Funder type Industry

Funder Name UCB Pharma Brussels (Belgium) - Research grant

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not provided at time of registration

Study outputs

Output type

Details Date created

Date added

Peer reviewed?

Patient-facing?

Results article	results	01/11/2014	
-----------------	---------	------------	--

Yes

No